Transient hyperthyroidism after withdrawal of antithyroid drugs in patients with Graves' disease

Endocrine Journal

Volumn 51, Issue 2, 2004, Pages 213-217

  Kubota, Sumihisa ^a   Tamai, Hajime ^b   Ohye, Hidemi ^a   Fukata, Shuji ^a   Kuma, Kanji ^a   Miyauchi, Akira ^a  

^a KUMA HOSPITAL   (Japan)

^b Eiko Hospital   (Japan)

Author keywords

ATD therapy; Graves' disease; Silent thyroiditis; Transient thyrotoxicosis

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE; THYROTROPIN; THYROTROPIN BINDING INHIBITOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MALE; RECURRENT DISEASE; RETROSPECTIVE STUDY; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADOLESCENT; ADULT; ANTITHYROID AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; MALE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; THYROTOXICOSIS; TIME FACTORS;

EID: 2442683266     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.51.213     Document Type: Article

References (23)

1. Schleusener H, Schwander J, Holl G, Badenehoop K, Hensen J, Finke R, Bogner U, Mayr WR, Schernthaner G, Schatz H, Pickardt CR, Kotulla P (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 120: 689-701.
2. Benker G, Vitti P, Kahalys G, Raue F, Tegler L, Hirche H, Reinwein D (1995) Response to methimazole in Graves' disease. Clin Endocrinol (Oxf) 43: 257-263.
3. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.
4. Eckel RH, Green WL (1980) Postpartum thyrotoxicosis in a patient with Graves' disease. Association with low radioactive iodine uptake. JAMA 243: 1454-1456.
5. Momotani N, Noh J, Ishikawa N, Ito K (1994) Relationship between silent thyroiditis and recurrent Graves' disease in the postpartum period. J Clin Endocrinol Metab 79: 285-289.
6. Papapetrou PD, Jackson IM (1975) Thyrotoxicosis due to "silent" thyroiditis. Lancet 1: 361-363.
7. Gluck FB, Nusynowitz ML, Plymate S (1975) Chronic lymphocytic thyroiditis, thyrotoxicosis, and low radioactive iodine uptake. Report of four cases. N Engl J Med 293: 624-628.
8. Check JH, Avellino J (1980) Painless thyroiditis and transient thyrotoxicosis after Graves' disease. JAMA 244: 1361.
9. Linde J, Friis T (1979) Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinol (Copenh) 91: 437-448.
10. Krolner B, Jorgensen JV, Nielsen SP (1983) Spinal bone mineral content in myxoedema and thyrotoxicosis: Effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 18: 439-446.
11. Toh SH, Claunch BC, Brown PH (1985) Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 145: 883-886.
12. Lee MS, Kim SY, Lee MC, Cho BY, Lee HK, Koh CS, Min HK (1990) Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 70: 766-770.
13. Gomez Acotto C, Schott AM, Hans D, Niepomniszcze H, Mautalen CA, Meunier PJ (1998) Hyperthyroidism influences ultrasound bone measurement on the Os calcis. Osteoporos Int 8: 455-459.
14. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K (1982) Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72: 903-906.
15. Klein I (1990) Thyroid hormone and the cardiovascular system. Am J Med 88: 631-637.
16. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331: 1249-1252.
17. Rosen CJ, Adler RA (1992) Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 75: 1531-1534.
18. Diamond T, Vine J, Smart R, Butler P (1994) Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 120: 8-11.
19. Wakasugi M, Wakao R, Tawata M, Gan N, Inoue M, Koizumi K, Onaya T (1994) Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry. Thyroid 4: 179-182.
20. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC (1994) Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 41: 421-424.
21. Arata N, Momotani N, Maruyama H, Saruta T, Tsukatani K, Kubo A, Ikemoto K, Ito K (1997) Bone mineral density after surgical treatment for Graves' disease. Thyroid 7: 547-554.
22. Rodney HF (2001) Atrial fibrillation. N Engl J Med 344: 1067-1078.
23. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Sacca L (1994) Control of adrenergic overactivity by β-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 78: 1028-1033.